Community-acquired pneumonia: An update on therapy

Alfred A. Lardizabal, Bonita T. Mangura

Research output: Contribution to journalReview articlepeer-review

Abstract

In the assessment of community-acquired pneumonia, an effort should be made to identify the causal pathogen, since this may permit more focused treatment. However, diagnostic testing should not delay appropriate empiric therapy. The selection of empiric therapy can be guided by a patient stratification system that is based on the severity of illness and underlying risk factors for specific pathogens. For example, outpatients who do not have underlying cardiopulmonary disease or other risk factors can be given azithromycin, clarithromycin, or doxycycline. Higher-risk outpatients should be given a β-lactam antibiotic plus azithromycin, clarithromycin, or doxycycline, or monotherapy with a fluoroquinolone. If the patient fails to respond to therapy, it may be necessary to do bronchoscopy; CT of the chest; or serologic testing for Legionella species, Mycoplasma pneumoniae, viruses, or other pathogens.

Original languageEnglish (US)
Pages (from-to)54-67
Number of pages14
JournalJournal of Respiratory Diseases
Volume27
Issue number2
StatePublished - Feb 2006

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Community-acquired pneumonia: An update on therapy'. Together they form a unique fingerprint.

Cite this